Paediatric multiple sclerosis: a new era in diagnosis and treatment

COMMENTED

Multiple Sclerosis

Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland

Mult Scler J Exp Transl Clin.

Kaufmann M, Kuhle J, Puhan MA, Kamm CP, Chan A, Salmen A, Kesselring J, Calabrese P, Gobbi C, Pot C, Steinemann N, Rodgers S, von Wyl V; Swiss Multiple Sclerosis Registry (SMSR)

doi: 10.1177/2055217318814562.

Multiple Sclerosis

A new era of multiple sclerosis rehabilitation: lessons from stroke

Lancet Neurol.

Ploughman M

doi: 10.1016/

Multiple Sclerosis

What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question

Pharmacol Res.

Pistono C, Osera C, Boiocchi C, Mallucci G, Cuccia M, Bergamaschi R, Pascale A

doi: 10.1016/

Multiple Sclerosis

Progressive multiple sclerosis: from pathogenic mechanisms to treatment

Brain.

Correale J, Gaitán MI, Ysrraelit MC, Fiol MP

doi: 10.1093/brain/aww258.

SPECIAL REPORT

Multiple Sclerosis

Vaccination Readiness in Multiple Sclerosis

SPECIAL REPORT

Multiple Sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

RECOMMENDED

Multiple Sclerosis

Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis

Lancet Neurol.

Ontaneda D, Tallantyre E, Kalincik T, Planchon SM, Evangelou N

doi: 10.1016/S1474-4422(19)30151-6.

Multiple Sclerosis

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis

Cochrane Database Syst Rev.

Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G

doi: 10.1002/

Multiple Sclerosis

Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study

Lancet Neurol.

Filippi M, Preziosa P, Meani A, Ciccarelli O, Mesaros S, Rovira A, Frederiksen J, Enzinger C, Barkhof F, Gasperini C, Brownlee W, Drulovic J, Montalban X, Cramer SP, Pichler A, Hagens M, Ruggieri S, Martinelli V, Miszkiel K, Tintorè M, Comi G, Dekker I, Uitdehaag B, Dujmovic-Basuroski I, Rocca MA

doi: 10.1016/

Related content

Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland

A new era of multiple sclerosis rehabilitation: lessons from stroke

What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question

Progressive multiple sclerosis: from pathogenic mechanisms to treatment

Vaccination Readiness in Multiple Sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis

Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study